Severity and outcomes of inpatient admissions for gamma hydroxy-butyrate withdrawal amidst COVID-19 pandemic in South Western Sydney

RICKY HARJANTO¹, ANTON DU TOIT², SANDRO SPERANDEI³, PRAKASH POUDEL¹, SAMANTHI ABEYWARDANA¹, KYLIE LOMBARDO¹, RICHARD HALLINAN¹,³, PETER MCCAUL¹, GILBERT WHITTON¹

¹South Western Sydney Local Health District Drug Health Services, New South Wales Health, Sydney, Australia, ²Translational Health Research Institute, Western Sydney University, Sydney, Australia, ³School of Medicine, University of Sydney, Sydney, Australia

Presenter’s email: ricky.harjanto@health.nsw.gov.au

Introduction and Aims: Dependence on Gamma-hydroxybutyrate, and its precursors gamma-Butyrolactone and 1,4-butandiol (henceforth GHB), is an emerging substance use disorder which is life-threatening in overdose and withdrawal. The aim of the project is to describe rising hospitalisations amidst the ongoing COVID-19 pandemic when illicit drug supply and demand and access to treatment services may be affected.

Design and Methods: This is a retrospective consecutive case series of adult patients admitted to hospitals in South Western Sydney Local Health District with clinical coding of GHB-related disorder between March 20, 2019 and March 20, 2021. Descriptive statistical analysis was performed on morbidity outcomes and multivariable Kaplan-Meier survival analysis on length of hospital stay by univariable analysis with p<0.3.

Results: 47 out of 84 (56%) GHB-related admissions among 68 patients involved GHB withdrawal, of which 36 of 47 (77%) were emergency presentations and 7 of 47 (15%) were re-admissions within the study period. 15 of 47 (32%) withdrawal-related admissions had a prior history of withdrawal seizures and/or delirium. 15 of 47 (32%) required intensive or one-to-one care, with 6 of 47 (13%) intubated, and 8 of 47 (17%) required ward emergency calls for agitated delirium (n=6), fall (n=1), or seizure (n=1). No patients died. 7 of 84 (8%) admitted patients self-discharged against medical advice. Five cofactors were significant in the multivariable analysis of length of hospital stay (p < 0.05): age 30 or older (HR 0.53 [0.29-0.95], p=0.03), six months of regular GHB use (HR 0.38 [0.21-0.70], p=0.002), elective admission (HR 0.44 [0.21-0.95], p=0.035), withdrawal presentation (HR 2.86 [1.16-7.03], p=0.022), and overdose presentation (HR 12.57 [3.97-39.77], <=0.001).

Implications for Practice or Policy: Development of a validated GHB withdrawal severity scale based on these risk factors can help identify patients with regular GHB use requiring closer monitoring for complicated withdrawal and escalation of care.

Disclosure of Interest Statement: The authors have no disclosures of interest to report.